These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30051651)

  • 21. A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy.
    Estepp JH; Smeltzer MP; Kang G; Li C; Wang WC; Abrams C; Aygun B; Ware RE; Nottage K; Hankins JS
    Am J Hematol; 2017 Dec; 92(12):1333-1339. PubMed ID: 28913922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy.
    Ware RE; Zimmerman SA; Sylvestre PB; Mortier NA; Davis JS; Treem WR; Schultz WH
    J Pediatr; 2004 Sep; 145(3):346-52. PubMed ID: 15343189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia.
    Wang WC; Wynn LW; Rogers ZR; Scott JP; Lane PA; Ware RE
    J Pediatr; 2001 Dec; 139(6):790-6. PubMed ID: 11743503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hydroxyurea effectiveness in children and adolescents with sickle cell anemia: A large retrospective, population-based cohort.
    Quarmyne MO; Dong W; Theodore R; Anand S; Barry V; Adisa O; Buchanan ID; Bost J; Brown RC; Joiner CH; Lane PA
    Am J Hematol; 2017 Jan; 92(1):77-81. PubMed ID: 27761932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stroke Recurrence in Nigerian Children With Sickle Cell Disease: Evidence for a Secondary Stroke Prevention Trial.
    Abdullahi SU; DeBaun MR; Jordan LC; Rodeghier M; Galadanci NA
    Pediatr Neurol; 2019 Jun; 95():73-78. PubMed ID: 30952488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing hydroxyurea therapy for sickle cell anemia.
    Ware RE
    Hematology Am Soc Hematol Educ Program; 2015; 2015():436-43. PubMed ID: 26637755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world experience using hydroxyurea in children with sickle cell disease in Lilongwe, Malawi.
    Mvalo T; Topazian HM; Kamthunzi P; Chen JS; Kambalame I; Mafunga P; Mumba N; Chiume M; Paseli K; Tegha G; Kumwenda W; Heimlich JB; Ellis G; Key N; Gopal S; Hoffman I; Ataga KI; Westmoreland KD
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27954. PubMed ID: 31397075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-dose hydroxycarbamide therapy may offer similar benefit as maximum tolerated dose for children and young adults with sickle cell disease in low-middle-income settings.
    Inusa BPD; Wale A; Hassan AA; Idhate T; Dogara L; Ijei I; Qin Y; Anie K; Lawson JO; Hsu L
    F1000Res; 2018; 7():. PubMed ID: 30228870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia.
    Heeney MM; Howard TA; Zimmerman SA; Ware RE
    J Lab Clin Med; 2003 Apr; 141(4):279-82. PubMed ID: 12677174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary prevention of stroke in children with sickle cell anemia in sub-Saharan Africa: rationale and design of phase III randomized clinical trial.
    Abdullahi SU; Wudil BJ; Bello-Manga H; Musa AB; Gambo S; Galadanci NA; Aminu H; Tijjani Gaya A; Sanusi S; Tabari MA; Galadanci A; Borodo A; Abba MS; Dambatta AH; Haliru L; Gambo A; Cassell H; Rodeghier M; Ghafuri DL; Covert Greene BV; Neville K; Kassim AA; Kirkham F; Trevathan E; Jordan LC; Aliyu MH; DeBaun MR
    Pediatr Hematol Oncol; 2021 Feb; 38(1):49-64. PubMed ID: 33236662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: A Phase III international randomized clinical trial.
    Hankins JS; McCarville MB; Rankine-Mullings A; Reid ME; Lobo CL; Moura PG; Ali S; Soares DP; Aldred K; Jay DW; Aygun B; Bennett J; Kang G; Goldsmith JC; Smeltzer MP; Boyett JM; Ware RE
    Am J Hematol; 2015 Dec; 90(12):1099-105. PubMed ID: 26414435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hydroxyurea therapy associated with declining serum levels of magnesium in children with sickle cell anemia.
    Altura RA; Wang WC; Wynn L; Altura BM; Altura BT
    J Pediatr; 2002 May; 140(5):565-9. PubMed ID: 12032523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydroxyurea treatment is associated with reduced degree of oxidative perturbation in children and adolescents with sickle cell anemia.
    Vinhaes CL; Teixeira RS; Monteiro-Júnior JAS; Tibúrcio R; Cubillos-Angulo JM; Arriaga MB; Sabarin AG; de Souza AJ; Silva JJ; Lyra IM; Ladeia AM; Andrade BB
    Sci Rep; 2020 Nov; 10(1):18982. PubMed ID: 33149225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary stroke prevention in Nigerian children with sickle cell disease (SPIN): challenges of conducting a feasibility trial.
    Galadanci NA; Abdullahi SU; Tabari MA; Abubakar S; Belonwu R; Salihu A; Neville K; Kirkham F; Inusa B; Shyr Y; Phillips S; Kassim AA; Jordan LC; Aliyu MH; Covert BV; DeBaun MR
    Pediatr Blood Cancer; 2015 Mar; 62(3):395-401. PubMed ID: 25399822
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea.
    Hankins JS; Helton KJ; McCarville MB; Li CS; Wang WC; Ware RE
    Pediatr Blood Cancer; 2008 Feb; 50(2):293-7. PubMed ID: 17554794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hydroxyurea Pharmacokinetics in Pediatric Patients After Total Pancreatectomy With Islet Autotransplantation.
    Boucher AA; Dong M; Vinks AA; Marahatta A; Howard TA; Ware RE; Nathan JD; Abu-El-Haija M; Luchtman-Jones L
    J Clin Pharmacol; 2021 Apr; 61(4):547-554. PubMed ID: 33029796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia.
    Estepp JH; Melloni C; Thornburg CD; Wiczling P; Rogers Z; Rothman JA; Green NS; Liem R; Brandow AM; Crary SE; Howard TH; Morris MH; Lewandowski A; Garg U; Jusko WJ; Neville KA;
    J Clin Pharmacol; 2016 Mar; 56(3):298-306. PubMed ID: 26201504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hydroxyurea lowers transcranial Doppler flow velocities in children with sickle cell anaemia in a Nigerian cohort.
    Lagunju I; Brown BJ; Sodeinde O
    Pediatr Blood Cancer; 2015 Sep; 62(9):1587-91. PubMed ID: 25847050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimizing Hydroxyurea use in children with sickle cell disease: low dose regimen is effective.
    Sharef SW; Al-Hajri M; Beshlawi I; Al-Shahrabally A; Elshinawy M; Zachariah M; Mevada ST; Bashir W; Rawas A; Taqi A; Al-Lamki Z; Wali Y
    Eur J Haematol; 2013 Jun; 90(6):519-24. PubMed ID: 23489171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of hydroxyurea treatment for patients with hemoglobin SC disease.
    Luchtman-Jones L; Pressel S; Hilliard L; Brown RC; Smith MG; Thompson AA; Lee MT; Rothman J; Rogers ZR; Owen W; Imran H; Thornburg C; Kwiatkowski JL; Aygun B; Nelson S; Roberts C; Gauger C; Piccone C; Kalfa T; Alvarez O; Hassell K; Davis BR; Ware RE
    Am J Hematol; 2016 Feb; 91(2):238-42. PubMed ID: 26615793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.